Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)

Clinical trial NCT05165407 · RECRUITING

Trial details

NCT number: NCT05165407
Sponsor: Peking University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Neoplasm

Start date: 2022-07-12
Primary completion: 2025-09-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.